Stock Rating: Will FBR & Co. Downgrade Harm Juno Therapeutics Inc (NASDAQ:JUNO) Stock Price Today?

November 24, 2016 - By Richard Conner

Stock Rating:  Will FBR & Co. Downgrade Harm Juno Therapeutics Inc (NASDAQ:JUNO) Stock Price Today?

Juno Therapeutics Inc (NASDAQ:JUNO) Downgrade

FBR & Co. downgraded Juno Therapeutics Inc (NASDAQ:JUNO)‘s stock to a “Mkt Perform” rating from “Outperform”. The ratings change was revealed to clients in a a note today. The firm currently has a $30.00 target on the stock.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 108.78% above today’s ($22.56) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, December 15 by Standpoint Research. On Wednesday, November 23 the stock rating was downgraded by FBR Capital to “Mkt Perform”. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by FBR Capital on Friday, July 8. The stock has “Buy” rating given by Standpoint Research on Monday, August 24. Maxim Group maintained the shares of JUNO in a report on Friday, August 5 with “Buy” rating. The firm has “Hold” rating given on Thursday, October 29 by Standpoint Research. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Outperform” rating by Northland Capital on Wednesday, July 22. The firm has “Outperform” rating given on Thursday, June 2 by Raymond James. On Friday, July 8 the stock rating was downgraded by JP Morgan to “Neutral”. The firm earned “Neutral” rating on Wednesday, November 18 by Goldman Sachs.

The stock decreased 24.50% or $7.32 on November 23, hitting $22.56. About 17.58M shares traded hands or 1112.41% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.

Susquehanna Llp has 101,172 shares for 0% of their US portfolio. Goldman Sachs has 0% invested in the company for 330,423 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 134,849 shares or 0.07% of their US portfolio. Springbok Mgmt Limited Liability, a New York-based fund reported 500 shares. Perceptive Advsr Ltd Liability Corporation accumulated 1,113 shares or 0% of the stock. Blackrock last reported 9,626 shares in the company. Rockefeller Fincl Svcs last reported 0% of its portfolio in the stock. Fred Alger Mgmt has 0.01% invested in the company for 35,692 shares. Moreover, Glob X Mgmt Ltd Liability Corporation has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 230 shares. Mutual Of America Cap Mgmt Limited Liability Company last reported 0% of its portfolio in the stock. First Trust Advsr Limited Partnership holds 0.09% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 703,197 shares. Moreover, First Allied Advisory has 0.05% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 21,152 shares. Baker Bros Advsr Lp has 0.03% invested in the company for 80,000 shares. Raymond James And Associates owns 5,839 shares or 0% of their US portfolio. Northern Tru holds 268,553 shares or 0% of its portfolio.

Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.27 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Nasdaq.com published: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” on November 23, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Fool.com and their article: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>